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I. Abstract
The major histocompatibility complex (MHC) is a gene family responsible for
many critical functions of the immune system in most vertebrates. The MHC
consists of three classes differentiated by their structure and function, and MHC
class I encodes antigen binding proteins as well as chaperone and accessory
proteins such as tapasin. The purpose of this project is to reconstitute several
human MHC class I molecules in their peptide-filled and peptide-deficient forms,
and to purify these proteins for biochemical study. The expressed proteins
include wild type and mutant variants of the fusion protein human leukocyte
antigen HLA-B*0801-fos, and human beta-2-microglobulin (β2m). The major
experiments performed for this project include: 1) transformation of engineered
plasmids into competent cells; 2) large scale protein production; 3) extraction and
purification of proteins as inclusion bodies; 4) reconstitution of proteins into their
native structure; 5) purification of refolded proteins. The purified MHC class I
molecules can be used to study their interactions with transmembrane chaperone
and accessory proteins that reside in the endoplasmic reticulum for the purpose
of better understanding the class I antigen presentation pathway.
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III. Introduction
The major histocompatibility complex (MHC) is a gene family responsible for
many critical functions of the immune system in most vertebrates. The MHC
consists of three classes differentiated by their structure and function, and MHC
class I encodes antigen binding proteins as well as chaperone and accessory
proteins such as tapasin. The purpose of this project is to reconstitute several
human MHC class I molecules in their peptide-filled and peptide-deficient forms,
and to purify these proteins for biochemical study. Purified MHC class I
molecules can be used to study their interactions with transmembrane chaperone
and accessory proteins that reside in the endoplasmic reticulum for the purpose
of better understanding the class I antigen presentation pathway.
The expressed proteins include wild type and mutant variants of the fusion
protein human leukocyte antigen HLA-B*0801-fos, and human beta-2microglobulin (β2m). The protein and nucleotide sequences of these genes are
listed in the appendix, section IX.1. HLA-B*0801-fos was specifically designed to
enhance in vitro interactions with tapasin-jun. Fos and jun interactions between
these proteins allow the B*0801 and tapasin portions of the proteins to be within
vicinity of one another, mimicking the environment in the Endoplasmic reticulum.
β2m is the small subunit of MHC class I molecule, including HLA-B*0801.
Association with β2m is generally required for the transport of class I heavy
chains from the endoplasmic reticulum to the cell surface.
Essential interaction regions between HLA-B*0801-fos and tapasin-jun can be
studied through experiments involving mutant variants of these proteins. The
location of these regions can be pinpointed by studying changes in interactions
between HLA-B*0801-fos and tapasin-jun mutated at specific residues.
Residues 222, 227 and 229 of the HLA-B*0801 protein are hypothesized to be
key regions of interaction with tapasin-jun. The series of experiments performed
in this project attempted to reconstitute wild type HLA-B*0801fos proteins and
HLA-B*0801fos proteins mutated at the specific residues 222, 227 and 229. In
addition, the experiments attempted to reconstitute β2m proteins of both wild
type and mutant variety.
The major experiments performed for this project include: 1) transformation of
engineered plasmids into competent cells; 2) large scale protein production; 3)
extraction and purification of proteins as inclusion bodies; 4) reconstitution of
proteins into their native structure; 5) purification of refolded proteins.
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IV. Experiment
IV.1 Plasmid preparation of PGMT7 with HLA-B*0801fos gene and PLM1
with β2m gene
Pure plasmid samples of PGMT7 containing the HLA-B*0801fos and PLM1
containing the β2m gene were extracted from a stock culture of previously
transformed DH5α cells. First, the cells were streaked on Luria-Bertani (LB) agar
plate with ampicillin and incubated overnight at 37°C. After incubation, cells that
contained the mutant plasmid formed colonies on the plate. An isolated colony
was selected and inoculated into 25ml of 2% LB nutrient broth and grown
overnight at 30°C.
Pelleted cells were collected from the 25ml culture by centrifugation. The pellets
were distributed into five 1.5ml microcentrifuge tubes. Plasmids were extracted
from these pelleted cells using the QIAspin miniprep kit from Qiagen. This
process yielded about a 500µl solution of pure plasmid. The plasmid solution
was concentrated to a final volume of 100µl through vacuum evaporation. The
plasmid was stored in a 1.5ml microcentrifuge tube at -20°C.
The final concentration of the plasmid solution was determined through mass
spectroscopy. 5µl of the solution was mixed with 495µl of sterilized water and
the optical density at 260nm wavelength (OD260) of the mixture was measured.
The concentration of the plasmid solution was determined by using the following
formulas IV.1.1 and IV.2.2.
C (µg/ml) = 50*A*D

(IV.1.1)

C (mM) = 0.15*A*D

(IV.2.2)

C = Concentration
A = Absorbance = OD260 of the mixture
D = Dilution factor = 100
A total of six plasmid preparations were made: two for wild type HLA-B*0801fos
and β2m genes, one for a mutant β2m gene, and three for each of the mutant
HLA-B*0801fos genes “222”, “227”, “229”.
IV.2 Induced substitution mutation of PGMT7 plasmid containing HLAB*0801fos and PLM1 plasmid containing β2m gene
Primers were designed to induce mutations in PGMT7 plasmids containing the
HLA-B*0801fos gene and PLM1 plasmids containing the β2m gene through a
polymerase chain reaction (PCR). A total of 4 sets of primers were designed
according to the QuikChangeTM XL Site Directed Mutagenesis Kit, as shown in
table IV.2.1. Three of these sets were used to induce a codon change in the
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HLA-B*0801fos gene and one was used to induce a codon change in the β2m
gene. The primers were synthesized by Tufts University Core Facility.
A set of forward and reverse primers, 125ng each, were combined with 10ng of
circular plasmid containing the targeted gene into a reaction buffer with 0.0002 M
Deoxyribonucleotide triphosphate (dNTP) and 1µl of Pfu DNA polymerase, with a
final volume of 50µl. Additionally, a control was made, which contained all the
contents of the experimental mixture except the circular plasmid. PCR was
performed by placing the solutions through a heating cycle outlined in Table
IV.2.2.
Gel electrophoresis was used to check the result of the PCR, using 0.8%
agarose gel and 5µl of the PCR product. The remainder of the product was
stored at -20°C. Four induced mutation experiments were performed, one for
each set of primers in table IV.2.1.
Table IV.2.1. Primers for Substitution Mutation
B8fos222: HLA-B*0801fos Residue 222 Glutamic Acid to Alanine
mutation
B8F222 forward primer :
5’ GGC AGC GGG ATG GCG CGG ACC AAA CTC AGG 3’
B8R222 reverse primer:
5’ CCT GAG TTT GGT CCG CGC CAT CCC GCT GCC 3’
B8fos227: HLA-B*0801fos Residue 227 Aspartic Acid to Alanine mutation
B8F227 forward primer:
5’ GGA CCA AAC TCA GGC CAC TGA GCT TGT GGA 3’
B8R227 reverse primer:
5’ GTC TCC ACA AGC TCA GTG GCC TGA GTT TGG 3’
B8fos229: HLA-B*0801fos Residue 229 Glutamic Acid to Alanine
mutation
B8F229 forward primer:
5’ CCA AAC TCA GGA CAC TGC GCT TGT GGA GAC 3’
B8R229 reverse primer:
5’ CTG GTC TCC ACA AGC GCA GTG TCC TGA GTT 3’
β2m58: β2m Residue 58 Lysine to Alanine mutation
β2mF58 forward primer:
5’ GTG GAG CAT TCA GAT TTG TCC TTT AGC GCG GAT TGG TCG TTT
TAT CTC TTG TAC TAC ACT 3’
β2mR58 reverse primer:
5’ CAG TGT AGT ACA AGA GAT AAA ACG ACC AAT CCG CGC TAA AGG
ACA AAT CTG AAT GCT CCA C 3’
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Table IV.2.2. Heating Cycle for Polymerase Chain Reaction
Temp (°C) time (s) cycles
95
60
1
95
50
60
18
50
68
540
68
60
1

IV.3 Pure plasmid preparation of PGMT7 with mutant HLA-B*0801fos gene
and PLM1 with mutant β2m gene
Products from the PCR reaction were treated with 1µl Dpn1 enzyme for two
hours to break down the circular plasmids containing the wild type gene and to
join the ends of the linear plasmids containing the specified mutated gene.
After Dpn1 digestion, 10µl of the mutant and control PCR products were added to
separate microcentrifuge tubes each containing 50ml of thawed DH5α competent
cells. In addition, 2.5µl of control puc19 plasmid was added to another 50ml of
competent cells. The mixtures were incubated in ice for 30 minutes, followed by
a 20 second heat shock at 37°C. After additional 2 minute incubation on ice,
950µl of LB medium is added to each mixture, followed by additional 1 hour
incubation at 37°C. Each of the mixtures were spread on Luria-Bertani plus
ampicillin (LBA) agar plates with the amount in the table IV.3.1
An isolated colony was selected from either plate 1 or 2 and inoculated into 25ml
LB nutrient broth and grown overnight at 30°C. 500µl of the culture was
combined with 15% glycerol and stored at -80°C for future use. Plasmids were
extracted from the remaining overnight culture by following the plasmid
preparation procedures described in section IV.1, and stored at -20°C. A sample
of the extracted plasmid was used for DNA sequencing by Tufts University Core
Facility to check if the mutated gene is present. Four sets of plasmids were
created that contained the specified gene and mutation according to table IV.2.1.
Table IV.3.1. LBA Agar Plate Contents for DH5α Transformation
plate content
amount
1 Mutant
200µl
2 Mutant
400µl
3 Control
200µl
4 Control
400µl
5 Control puc19 100µl
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IV.4 Transformation of PGMT7 plasmids with mutant HLA-B*0801fos gene
and PLM1 plasmids with mutant β2m gene into protein producing
competent cells
PGMT7 plasmids with mutant HLA-B*0801fos gene were transformed into BL21
(DE3) competent cells, while PLM1 plasmids with mutant β2m gene were
transformed into BL21 (DE3) PLysS competent cells.
Two microcentrifuge tubes containing 100µl of thawed competent cells were
each treated with 1.7µl of β-mercaptoethanol and incubated in ice for 10 minutes.
Cells from the first tube were transformed with 1µl of plasmid solution containing
the target mutant gene. Also, 1µl of puc18 plasmid solution was added to the
second tube for use as a control. After additional 30 minute incubation in ice,
contents in each tube were heat shocked at 42°C for 45 seconds, followed by 2
minute ice incubation. The two tubes are then placed in a 37°C incubator for 1
hour. Each of the mixtures were spread on LB agar plates containing the
appropriate antibiotic, and in the amount shown in table IV.4.1. These plates
were incubated overnight at 37°C and used for expression test as described in
section IV.5
Table IV.4.1. LBA Agar Plate Contents for BL21 Transformation
host strain
antibiotics used
BL21 (DE3)
ampicillin
BL21 (DE3) PLysS ampicillin, chloramphenicol
plate content
1 Mutant
2 Mutant
3 Control puc18

amount
100µl
200µl
100µl

IV.5 Protein Expression Test of transformed BL21 (DE3) and BL21 (DE3)
PLysS cells
5 isolated colonies were selected from either plate 1 or 2 from experiment IV.4
and inoculated into separate sterile tubes each containing 2ml LBA nutrient broth
and grown overnight at 30°C. Afterwards, 50µl was taken from each of these
cultures and combined with 4.95ml of LB nutrient agar to make 1/100 dilutions.
The diluted cultures were placed in a shaker set at 37°C for about 3 hours, until
the contents reached an optical density at 600nm wavelength of OD600 = 0.600.
300µl were collected from each culture and pelleted cells were separated from
the supernatant and placed aside in separate 1.5 ml microcentrifuge tubes, and
stored at -20°C. Also, 500µl from each tube was collected to create 15% glycerol
stock cultures for future use. The remaining cultures were induced with 1mM
IPTG and returned to the shaker for additional 3 hour incubation. Another 300ml
were collected from each tube and the pelleted cells were stored in separate
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microcentrifuge tubes for SDS gel electrophoresis testing. The remaining
cultures were disposed.
The collected cells were each combined with 40µl of loading buffer and boiled at
100°C for 5 minutes, then centrifuged. 20µl of the supernatant from each tube
were applied to 12% SDS gel for HLA-B*0801fos, and 15% SDS gel for Β2m.
For each gel, electrophoresis was conducted for 100 minutes at 130V and 2A.
The finished gels were stained and used to confirm protein expression of the
targeted mutant genes.
IV.6 Inclusion body Preparation of mutant HLA-B*0801fos β2m proteins
Cells from a stock culture containing the target gene, made from section IV.5,
were streaked on an LB agar plate with ampicillin (and chloramphenicol for BL21
(DE3) PLysS) and incubated overnight. An isolated colony from the plate was
selected and inoculated into 50ml LB nutrient broth and grown overnight at 30°C.
10µl was taken from the culture and added to a flask containing 990ml LB
nutrient broth and 0.4% glucose to make a 1/100 dilution. Four of these flasks
were prepared for a total of 4 liters of culture. The diluted cultures were placed in
a shaker set at 37°C for about 3 hours, until the contents reached OD600 = 0.600.
1ml were collected from each culture and the pelleted cells placed aside in
separate 1.5ml microcentrifuge tubes and stored at -20°C. The remaining
cultures were induced with 1mM IPTG and returned to the shaker for additional 3
hour incubation. Another 1000ml were collected from each tube and the pelleted
cells were stored in separate microcentrifuge tubes for SDS polyacrylamide gel
electrophoresis (SDS-PAGE).
Pelleted cells were collected from the remaining culture by centrifugation. The
cells were then homogenized in 20ml of sucrose solution (table IV.6.1) and then
lysed by adding 75ml of deoxycholate/triton solution (table IV.6.2)with 30mg of
lysozyme. The lysing reaction lasted 20 minutes, at which the solution became
very viscous. 5mM of magnesium chloride and 5-10mg deoxyribonuclease I was
added to the solution to break the viscosity.
The solution was frozen using liquid nitrogen and then thawed in warm water, at
which 1ml of 1M MgCl2 and 1ml 0.5 M EDTA was then added. All the contents
were placed into 50ml centrifuge tubes and spun at 8000 rpm and at 4°C for 20
minutes.
The supernatants were discarded and the pellets were suspended in 40 ml of
Triton solution (table IV.6.3) and homogenized. The homogenized mixture was
once again placed into 50ml centrifuge tubes and spun at 8000 rpm and 4°C for
20 minutes. This washing procedure was done three times. Pellets collected
after three washes underwent a forth wash following the same procedures except
that Triton solution was substituted with Tris solution (table IV.6.4).
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Pellets collected after the forth wash were dissolved and homogenized in 10ml
Urea solution (table IV.6.5), and then placed into 10 1.5ml microcentrifuge tubes
and spun at 12000 rpm and at room temperature for 10 minutes. The
supernatants were aliquoted into 10 1.5 ml microcentrifuge tubes and frozen at 80°C.
Bradford assay was used to determine the concentration of the collected
inclusion bodies. A standard absorbance versus concentration curve was
created using stock 2 mg/ml bovine serum albumin (BSA) with the dilutions
outlined in table IV.6.6. 100ul of each dilution was added to 5ml of 20% Bradford
dye and the OD at 595nm wavelength was measured. This curve was used to
calculate the unknown concentration of the inclusion bodies based on its
measurable OD and known dilution factor.
Table IV.6.1. Sucrose Solution
reagent
Concentration
Tris pH 8.0
50mM
sucrose
25%
EDTA
1mM
Sodium Azide 0.10%
Table IV.6.2. Deoxycholate/triton Solution
reagent
Concentration
Deoxycholate 1%
Triton x100
1%
Tris pH7.5
20mM
Sodium Chloride 0.1M
Sodium Azide 0.10%
Table IV.6.3. Triton Solution
reagent
Concentration
Triton x100
0.50%
Tris
50mM
Sodium Chloride 100mM
EDTA
1mM
Sodium Azide 0.10%
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Table IV.6.4. Tris Solution
reagent
Concentration
Tris
50mM
EDTA
1mM
Sodium Azide 0.10%
Table IV.6.5. 8M Urea Solution
reagent
Concentration
Urea
8M
MES pH6
25mM
EDTA
1mM
DTT
0.1mM
Table IV.6.6. Bradford Assay Standard Dilutions
Concentration
0mg/ml 0.2mg/ml 0.4mg/ml 0.6mg/ml 0.8mg/ml
BSA (2mg/ml)
0µl
50µl
100µl
150µl
200µl
8M Urea
500µl
450µl
400µl
350µl
300µl
IV.7 Refolding HLA-B*0801fos Inclusion Bodies
Table IV.7.1 lists the components in the refolding buffer that was used to refold
the inclusion bodies into their native structure. First, 2µm of Β2m inclusion was
added to the refolding buffer, followed by 10mg of synthetic peptide dissolved in
100ml DMSO, and finally 1µm of the HLA-B*0801fos heavy chain.
The mixture was stored at 4°C for 48 hours, and then placed in 10000 MWCO
dialysis bags, which were placed in 10L 20mM Tris dialysis buffer (table IV.7.2).
The dialysis procedure lasted 24 hours, at which then concentration procedures
began.
Contents from the dialysis bags were concentrated to a volume of 15-30ml using
the Stir Cell apparatus, using 10000 MWCO membranes. The contents from the
Stir Cell were then placed in 1-2 Centripreps and concentrated to a final volume
of about 1ml and placed in a 1.5ml microcentrifuge tubes and spun at 12000 rpm
and at 4°C for 30 minutes. The supernatant, which contained refolded HLAB*0801fos and β2m, were transferred to another clean 1.5ml microcentrifuge
tube.
Refolded HLA-B*0801fos and β2m were each separated from aggregates and
other unwanted items according to their mass by using a fast protein liquid
chromatography (FPLC) system. The collected purified HLA-B*0801fos and β2m
were placed into a 10000 MWCO and a 3000 MWCO Centriprep, respectively,
and each concentrated to 1ml.
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The final concentrations of the samples were determined using mass
spectroscopy. 5µl from a sample was combined with 600µl of 6M Guanidine
Hydrochloride and stored at room temperature for one hour. The OD of this
mixture was measured and used to calculate the concentration of the sample
using formulas IV.7.1 and IV.7.2.
C(M) = A/E*D
C(mg/ml) = A/E*D*MW

(IV.7.1)
(IV.7.2)

C = concentration
A = absorbance = OD280
D = dilution factor = 605/5
MW HLA-B*0801fos = 50080kDa
MW β2m = 11400kDa
Table IV.7.1. 1L Refolding Buffer
reagent
Concentration (mM)
Tris pH 8
50mM
Arginine pH8 400mM
EDTA pH 8
1mM
GSSH
0.5mM
GSSG
0.5mM
PMSF
0.5mM
Water

Comments
50 ml added from 1M stock
200 ml added from 200ml stock (filtered)
2ml added from stock 0.5M
1.5g added directly
0.38g added direclty
2.5ml of 200mM fresh stock added
add up to 1L

Table IV.7.2. 20mM Tris buffer
reagent
Concentration (mM)
Tris pH 8
20mM
Sodium Chloride 150mM
IV.8 Creating peptide-less HLA-B*0801fos proteins
From IV.7, 500µl of refolded HLA-B*0801fos was denatured in 1500µl of 8M
Guanidine Hydrochloride (table IV.8.1) and stored at room temperature for 4
hours. The HLA-B*0801fos heavy chain was separated from Β2m using the
FPLC with 6M Guanidine Hydrochloride gel filtration buffer. The collected HLAB*0801fos was combined with the collected β2m and additional β2m from other
sources, if necessary, such that the molar ratio is 1:2 Heavy chain to β2m.
The mixture was diluted with 6M Guanidine Hydrochloride (table IV.8.2) to a
concentration of 1mg HLA-B*0801fos per 1ml, and placed in 3000 MWCO
dialysis bags and dialyzed against 1L of 8M Urea buffer (table IV.8.3) for 24
hours at 15°C. The dialysis buffer was then changed to 1L of 20mM Tris (table
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IV.7.2) plus 10% Glycerol for 16 hours, at which then the buffer was replaced
with another 1L of 20mM Tris plus 10% Glycerol. This process was done for 48
hours and 3 1L 20mM Tris plus 10% Glycerol buffers were used.
The dialyzed contents were concentrated to 30 ml using a Stir Cell and then to
1ml using a Centriprep. Pure peptide-less folded HLA-B*0801fos was collected
from the concentrated sample using the FPLC with 20mM Tris gel filtration buffer,
followed by a final Centriprep concentration to 1ml. The final concentration of
the sample was determined using mass spectroscopy as described in IV.7
Table IV.8.1. 8M Guanidine Hydrochloride
reagent
Concentration
Guanidine Hydrochloride 8M
Sodium Chloride
150mM
Tris pH 7.5
20mM
Table IV.8.2. 6M Guanidine Hydrochloride
reagent
Concentration
Guanidine Hydrochloride 6M
Sodium Chloride
150mM
Tris pH 7.5
20mM
Table IV.8.3. 8M Urea Buffer
reagent
Concentration
Urea
8M
MES pH6
25mM
EDTA
1mM
DTT
0.1mM
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V. Results and Discussion
V.1 Plasmid preparation of PGMT7 with HLA-B*0801fos gene and PLM1
with β2m gene
The final concentration of the PGTM7 plasmid solution with HLA-B*0801fos gene
was 380 µg/ml and was sufficient for further PCR experiments. Absorbance for
the solution was low at OD260 = 0.076 and a lower dilution factor can be used to
increase this value to be in the range of 0.1 – 0.9. An increase in plasmid yield
can be obtained by increasing the amount of cell culture used.
V.2 Induced substitution mutation of PGMT7 plasmid containing HLAB*0801fos and PLM1 plasmid containing β2m gene
Gel electrophoresis results of several PCR mutation reaction products are shown
in figures V.2.1 – V.2.3. PCR results with B8fos222 primers (figure V.2.1) were
somewhat inconclusive as the bands for control (lane 4) and mutant (lane 5)
were quite faint and can only be seen under careful inspection of the gel itself.
The photograph of the gel renders these bands invisible. These results indicated
that 5µl of sample may not be enough. For PCR reactions using B8fos227,
B8fos229 and β2m58 primers, 10µl of the products were used for gel
electrophoresis, which produced much better clarity, as shown by figures V.2.2 –
V.2.4.. Despite the lack of clarity of the 222 gel, the results confirm that the PCR
reactions were successful.

Figure V.2.1. PCR results with B8fos222 primers. Starting from the left, lanes 1
and 3 are makers, lane 4 is control and lane 5 is the mutant. Lane 4 contains no
bands near 30kb, which shows that PCR did not occur for the control. Although
not visible in this photo, a faint band is present in lane 5 at the location indicated
by the arrow near 30kb, showing that the PCR reaction was successful and that
the plasmids were produced.
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Figure V.2.2. PCR results with B8fos227 primers. Starting from the left, lane 1 is
a maker, lane 3 is the mutant and lane 6 is the control. Lane 3 contains only one
band at around 30kb, which suggests that all the primers were used up to create
mutant plasmids. Lane 6 contains a strong band near 50b, which represents
unused 227 primers.

Figure V.2.3. PCR results with B8fos229 primers. Starting from the left, lane 1 is
a maker, lane 3 is the mutant and lane 5 is the control. A band at around 30kb,
suggests that the PCR reaction was successful and plasmids were replicated.
Lane 5 contains a strong band near 50b, which represents unused 229 primers.
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Figure V.2.4. PCR results with β2m58 primers. Starting from the left, lane 1 is a
maker, lane 2 is the mutant and lane 3 is the control. A band at around 30kb for
lane 1 suggests that the PCR reaction was successful and plasmids were
replicated.
V.3 Pure plasmid preparation of PGMT7 with mutant HLA-B*0801fos gene
and PLM1 with mutant β2m gene
The transformation results for each plasmid were expected. Colony growth was
observed in LBA agar plates with competent cells strains transformed with a
mutant sample from PCR or the control puc19 plasmid. Cells transformed with a
control sample from PCR did not form colonies on LBA agar plates.
The sequencing results each plasmid are in Appendix – IX.3. The results show
that induced mutation using primers B8fos222, B8fos227, and B8fos229 were
successful and produced the specified point mutation. However, the first β2m
mutation was unsuccessful as the sequencing results show a combination of
insertion and frameshift mutations in the β2m gene, as opposed to the expected
point substitution mutation. The original set of primers (see Appendix – IX.2) had
a melting temperature slightly lower than the recommended values according to
the QuikChangeTM XL Site Directed Mutagenesis Kit and was also relatively short
compared to the primers B8fos222, B8fos227 and B8fos229. A second set of
primers were designed to carry out the β2m mutation and is listed in table IV.2.1.
This primer set was significantly longer than the first set and induces additional
point mutations, but the codons remain unchanged. Sequencing results
indicates that PCR using this primer yielded the expected point mutation in the
β2m gene contained in the PLM1 plasmid.
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V.4 Transformation of PGMT7 plasmids with mutant HLA-B*0801fos gene
and PLM1 plasmids with mutant β2m gene into protein producing
competent cells
The transformation results for each plasmid were expected. Colony growth was
observed in LBA or LBAC agar plates with competent cells strains transformed
with a mutant sample from PCR or the control puc18 plasmid. Cells transformed
with a control sample from PCR did not form colonies on LBA or LBAC agar
plates.
V.5 Protein Expression Test of transformed BL21 (DE3) and BL21 (DE3)
PLysS cells
SDS-PAGE results of several expression tests are shown in figures V.6.1 –
V.6.3. Leaked expression was observed for expression tests for the BL21 (DE3)
strain transformed with PGMT7 plasmids containing the B8fos222, B8fos227,
B8fos229 mutations. This problem was not observed in the expression test done
with the BL21 (DE3) PLysS strain transformed with PLM1 plasmids containing
the β2m58 mutation. Despite leaked expression, the results confirmed that the
transformed cells produced the specified proteins.

Figure V.5.1. SDS-PAGE result of B8fos222 expression test. Starting from the
left, lane 1 is a maker, lanes 2,4,6,8 are cells contents before IPTG induction.
Lanes 3,5,7,9 are cells after induction. Dominant bands near 35 kDa suggested
that HLA-B*0801fos proteins were produced.
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Figure V.5.2. SDS-PAGE result of B8fos227 expression test. Starting from the
left, lane 1 is a maker, lanes 2,4,6,8 are cells contents before IPTG induction.
Lanes 3,5,7,9 are cells after induction. Bands near 35 kDa suggested that HLAB*0801fos proteins were produced, although large amounts of other proteins
were produced as well.

Figure V.5.3. SDS-PAGE result of B8fos229 expression test. Starting from the
left, lane 1 is a maker, lanes 2,4,6,8 are cells contents before IPTG induction.
Lanes 3,5,7,9 are cells after induction. Dominant bands near 35 kDa suggested
that HLA-B*0801fos proteins were produced.
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Figure V.5.4. SDS-PAGE result of β2m58 expression test. Starting from the left,
lane 1 is a maker, lanes 2,4,6,8 are cells contents before IPTG induction. Lanes
3,5,7,9 are cells after induction. Dominant bands near 16 kDa for lanes 3,5,7,9
suggested that HLA-B*0801fos proteins were produced. The use of BL21 (DE3)
PLysS cell line may have prevented leaked expression.
V.6 Inclusion body Preparation of mutant HLA-B*0801fos β2m proteins
SDS-PAGE results of the inclusion bodies are shown in figures V.6.1 – V.6.3.
For HLA-B*0801fos, lanes that have a large band near 36 kDa compared with
other relatively weak bands shows that the inclusion body preparations contained
mostly HLA-B*0801fos protein and small amounts of other proteins. A large
band near 16 kDa for β2m also confirms that the inclusion body preparation
contained mostly β2m proteins.

Figure V.6.1. SDS-PAGE result of B8fos222 inclusion bodies. Lanes 4,5,6,7 are
inclusion body samples after each subsequent wash, with lane 4 being after the
first wash. The dominant bands observed at these lanes are near 36 kDa.
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Figure V.6.2. SDS-PAGE result of B8fos227 inclusion bodies. Lanes 4,5,6,7 are
inclusion body samples after each subsequent wash, with lane 4 being after the
first wash. The dominant bands observed at these lanes are near 36 kDa.

Figure V.6.3. SDS-PAGE result of B8fos229 inclusion bodies. Lanes 4,5,6,7 are
inclusion body samples after each subsequent wash, with lane 4 being after the
first wash. Lane 3 contains inclusion body sample before any wash. The
dominant bands observed at these lanes are near 36 kDa.
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Figure V.6.4. SDS-PAGE result of β2m58 inclusion bodies. Lanes 4,5,6,7 are
inclusion body samples after each subsequent wash, with lane 4 being after the
first wash. Lane 3 contains inclusion body sample before any wash. The
dominant bands observed towards the bottom of these lanes are near 16 kDa.
V.7 Refolding HLA-B*0801fos Inclusion Bodies
Chromatograph results from FPLC purification of HLA-B*0801fos proteins are
shown in Figure V.7.1. Generally, the HLA-B*0801fos peak is at 29 minutes,
followed by excess β2m proteins at 38 minutes. The aggregate peak at 18
minutes varies in strength depending on the concentration of the sample. A high
concentration usually resulted in a high aggregate peak (figure V.7.1) whereas a
low concentration yielded a low peak (figure V.7.2).

Figure V.7.1. Chromatograph of FPLC purification of HLA-B*0801fos proteins. A
1L refold was concentrated to 500ml before purification. The high concentration
lead to a large aggregate peak.
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Figure V.7.2. Chromatograph of FPLC purification of HLA-B*0801fos proteins. A
1L refold was concentrated to 5ml before purification. The low concentration
significantly reduced the aggregate peak and lead to a larger HLA-B*0801fos
peak.
V.8 Creating peptide-less HLA-B*0801fos Proteins
Chromatograph results from FPLC purification of denatured HLA-B*0801fos
proteins are shown in Figure V.8.1, and results from FPLC purification of refolded
peptide-less HLA-B*0801fos proteins are shown in Figure V.8.2. Aggregates are
almost undetectable by these chromatographs as they have been removed from
previous purifications.
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Figure V.8.1. Chromatograph of FPLC purification of denatured HLA-B*0801fos
proteins. The first large peak represents denatured HLA-B*0801fos and the
second peak represents denatured β2m

Figure V.8.2. Chromatograph of FPLC purification of peptide-less HLAB*0801fos proteins. The first large peak represents peptide-less HLA-B*0801fos
proteins and the second peak represents excess refolded β2m.
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VI. Conclusion
Inclusion body preparation of mutant HLA-B*0801-fos and β2m was successful,
as well as the reconstitution of wild type HLA-B*0801-fos protein in both peptidefilled and peptide deficient forms. Several unexpected problems occurred during
the series of experiments. First, the first set of mutations that involved the β2m
primers in IX.1.2 did not produce the desired codon change. As a result, the
primers were redesigned and the second mutation attempt produced the
expected results. Second, an unusual amount of aggregates were formed in the
refolding process for HLA-B*0801-fos. This problem was overcome by
decreasing the concentration at which the sample was purified. Other than these
minor problems, the experiments proceeded as expected and yielded acceptable
results.
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IX. Appendix
IX.1 DNA sequences of HLA-B*0801fos gene and β2m gene
IX.1.1 Human Leukocyte Antigen HLA-B*0801fos
1 atgctggtca tggcgccccg aaccgtcctc ctgctgctct cggcggccct ggccctgacc
61 gagacctggg ccggctccca ctccatgagg tatttcgaca ccgccatgtc ccggcccggc
121 cgcggggagc cccgcttcat ctcagtgggc tacgtggacg acacgcagtt cgtgaggttc
181 gacagcgacg ccgcgagtcc gagagaggag ccgcgggcgc cgtggataga gcaggagggg
241 ccggagtatt gggaccggaa cacacagatc ttcaagacca acacacagac tgaccgagag
301 agcctgcgga acctgcgcgg ctactacaac cagagcgagg ccgggtctca caccctccag
361 agcatgtacg gctgcgacgt ggggccggac gggcgcctcc tccgcgggca taaccagtac
421 gcctacgacg gcaaggatta catcgccctg aacgaggacc tgcgctcctg gaccgcggcg
481 gacaccgcgg ctcagatcac ccagcgcaag tgggaggcgg cccgtgtggc ggagcaggac
541 agagcctacc tggagggcac gtgcgtggag tggctccgca gatacctgga gaacgggaag
601 gacacgctgg agcgcgcgga ccccccaaag acacacgtga cccaccaccc catctctgac
661 catgaggcca ccctgaggtg ctgggccctg ggcttctacc ctgcggagat cacactgacc
721 tggcagcggg atggcgagga ccaaactcag gacactgagc ttgtggagac cagaccagca
781 ggagatagaa ccttccagaa gtgggcagct gtggtggtgc cttctggaga agagcagaga
841 tacacatgcc atgtacagca tgaggggctg ccgaagcccc tcaccctgag atgggagccg
901 tcttcccagt ccaccgtccc catcgtgggc attgttgctg gcctggctgt cctagcagtt
961 gtggtcatcg gagctgtggt cgctgctgtg atgtgtagga ggaagagctc aggtggaaaa
1021 ggagggagct actctcaggc tgcgtgcagc gacagtgccc agggctctga tgtgtctctc
1081 acagcttga
/translation=MLVMAPRTVLLLLSAALALTETWA
GSHSMRYFDTAMSRPGRGEP
RFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNTQIFKTNTQTDRESL
RNLRGYYNQSEAGSHTLQSMYGCDVGPDGRLLRGHNQYAYDGKDYIALNEDLRSWTAA
DTAAQITQRKWEAARVAEQDRAYLEGTCVEWLRRYLENGKDTLERADPPKTHVTHHPI
SDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSG
EEQRYTCHVQHEGLPKPLTLRWEPSSQSTVPIVGIVAGLAVLAVVVIGAVVAAVMCRR
KSSGGKGGSYSQAACSDSAQGSDVSLTA
Soluble domain of B0801 Heavy chain
GSHSMRYFDTAMSRPGRGEP
RFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNTQIFKTNTQTDRESL
RNLRGYYNQSEAGSHTLQSMYGCDVGPDGRLLRGHNQYAYDGKDYIALNEDLRSWTAA
DTAAQITQRKWEAARVAEQDRAYLEGTCVEWLRRYLENGKDTLERADPPKTHVTHHPI
SDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSG
EEQRYTCHVQHEGLPKPLTLRWE
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IX.1.2 Human beta-2-microglobulin (β2m)
iqrtpkiqvy srhpaengks nflncyvsgf hpsdievdll kngeriekve hsdlsfskdw sfyllyytef
tptekdeyac rvnhvtlsqp kivkwdrdm
(Ribosome binding site) (atg)
61 atccagcgta ctccaaagat tcaggtttac tcacgtcatc cagcagagaa tggaaagtca
121 aatttcctga attgctatgt gtctgggttt catccatccg acattgaagt tgacttactg
181 aagaatggag agagaattga aaaagtggag cattcagact tgtctttcag caaggactgg
241 tctttctatc tcttgtacta cactgaattc acccccactg aaaaagatga gtatgcctgc
301 cgtgtgaacc atgtgacttt gtcacagccc aagatagtta agtgggatcg agacatgtaa
Ribosome binding site = aag gag gat att aaa
IX.2 Original B2m primers
β2m58: β2m Residue 58 Lysine to Alanine mutation
β2mF58 forward primer:
5’ CAG ACT TGT CTT TCA GCG CGG ACT GGT CTT TCT ATC TC 3’
β2mR58 reverse primer:
5’ GAG ATA GAA AGA CCA GTC CGC GCT GAA AGA CAA GTC TG 3’
IX.3 Plasmid sequencing results of mutant PGMT7 and β2m from TUFTS
University Core Facility in FASTA format
>B82221-B44-2
NgcgGcggAaCCGCGGCTCAGATCACCCAGCGCAAGTGGGAGGCGGCCCGTGTGGCGGAgC
AGGACAGAGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGGAGAACG
GGAAGGACACGCTGGAGCGCGCGGACCCCCCAAAGACACACGTGACCCACCACCCCATCT
CTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCGGAGATCACACT
GACCTGGCAGCGGGATGGCGCGGACCAAACTCAGGACACTGAGCTTGTGGAGACCAGACC
AGCAGGAGATAGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAGCA
GAGATACACATGCCATGTACAGCATGAGGGGCTGCCGAAGCCCCTCACCCTGAGATGGGA
GGGAGGTTCCGGCGGTCTGGTTCCGCGTGGCTCGTTAACTGATACACTCCAAGCGGAGACA
GATCAACTTGAAGACGAGAAGTCTGCGTTGCAGACCGAGATTGCCAATCTACTGAAAGAGAA
GGAAAAACTGGAGTTCATCCTGGCCGCCCATTAAAAGCTTGAATTCCGATCCGGCTGCTAAC
AAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCC
TTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATAA
TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAAT
GGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTAT
TTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATA
ATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGA
AATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCNANNTAGGGGTTNANNN
>B82221-B44-1
AGCgcagGTCCTCGTTCAGGGCGATGTAATCCTTGCCGTCGTAGGCGTACTGgTTaTGCCCG
CGGAGGAGGCGCCCGTCCGGCCCCACGTCGCAGCCGTACATGCTCTGGAGGGTGTGAGA
CCCGGCCTCGCTCTGGTTGTAGTAGCCGCGCAGGTTCCGCAGGCTCTCTCGGTCAGTCTGT
GTGTTGGTCTTGAAGATCTGTGTGTTCCGGTCCCAATACTCCGGCCCCTCCTGCTCTATCCA

27

CGGCGCCCGCGGCTCCTCTCTCGGACTCGCGGCGTCGCTGTCGAACCTCACGAACTGCGT
GTCGTCCACGTAGCCCACTGAGATGAAGCGGGGCTCCCCGCGGCCGGGCCGGGACATGG
CGGTGTCGAAATACCTCATGGAGTGGGATCCCATATGTATATCTCCTTCTTAAAGTTAAACAA
AATTATTTCTAGAGGGAAACCGTTGTGGTCTCCCTATAGTGAGTCGTATTAATTTCGCGGGAT
CGAGATCCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCC
GGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGC
GTCAGCGGGTGTTGGCGGGTGTCGGGGCGCAGCCATGACCCAGTCACGTAGCGATAGCGG
AGTGTATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATTGCGG
TGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCCTC
GCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGNATCAGCTCACTCAAA
GGCGGTANTACNGGTTATCCACAGAATCNGGGGANNACGCAGNAAAGAACATGTGAGCAAA
NNNNGCAAAANGCNAGNAANCGTAAAAAGGCCNCGTNGCTGGNGTTTTTNCNNNAGGNNTC
CNNNCCCCNNN
>B82221-T7
CcTCTagaataaTTTTGTTTAACTTTAAGAAGGAGATATACATATGGGATCCCACTCCATGAGGT
ATTTCGACACCGCCATGTCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATCTCAGTGGGCT
ACGTGGACGACACGCAGTTCGTGAGGTTCGACAGCGACGCCGCGAGTCCGAGAGAGGAGC
CGCGGGCGCCGTGGATAGAGCAGGAGGGGCCGGAGTATTGGGACCGGAACACACAGATCT
TCAAGACCAACACACAGACTGACCGAGAGAGCCTGCGGAACCTGCGCGGCTACTACAACCA
GAGCGAGGCCGGGTCTCACACCCTCCAGAGCATGTACGGCTGCGACGTGGGGCCGGACG
GGCGCCTCCTCCGCGGGCATAACCAGTACGCCTACGACGGCAAGGATTACATCGCCCTGAA
CGAGGACCTGCGCTCCTGGACCGCGGCGGACACCGCGGCTCAGATCACCCAGCGCAAGTG
GGAGGCGGCCCGTGTGGCGGAGCAGGACAGAGCCTACCTGGAGGGCACGTGCGTGGAGT
GGCTCCGCAGATACCTGGAGAACGGGAAGGACACGCTGGAGCGCGCGGACCCCCCAAAGA
CACACGTGACCCACCACCCCATCTCTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGG
GCTTCTACCCTGCGGAGATCACACTGACCTGGCAGCGGGATGGCGCGGACCAAACTCAGG
ACACTGAGCTTGTGGAGACCAGACCAGCAGGAGATAGAACCTTCCAGAAGTGGGCAGCTGT
GGTGGTGCCTTCTGGAGAAGAGCAGAGATACACATGCCATGTACAGCATGAGGGGCTGCC
GAAGCCCCTCACCCTGAGATGGGAGGGAGGTTCCGGCGGTCTGGTTCCGCGTGGCTCGTT
AACTGATACACTCCAAGCGGAGACAGATCAACTTGAAGACGAGAAGTCTGCGTTGCAGACC
GAGATTGCCAATCTACTGAAAGAGAANGGAAAAACTGGGANTTCATCCNGNNNNCCCATTAA
AAGCTNGAATTCCGATNCNGCNGNNTAACAANGCCCCGN
>B82221-T7-Term
cttcttTCGGGCTTTGTTAGCAGCCGGATCGGAATTCAAGCTTTTAATGGGCGGCCAGGATGAA
CTCCAGTTTTTCCTTCTCTTTCAGTAGATTGGCAATCTCGGTCTGCAACGCAGACTTCTCGTC
TTCAAGTTGATCTGTCTCCGCTTGGAGTGTATCAGTTAACGAGCCACGCGGAACCAGACCG
CCGGAACCTCCCTCCCATCTCAGGGTGAGGGGCTTCGGCAGCCCCTCATGCTGTACATGGC
ATGTGTATCTCTGCTCTTCTCCAGAAGGCACCACCACAGCTGCCCACTTCTGGAAGGTTCTA
TCTCCTGCTGGTCTGGTCTCCACAAGCTCAGTGTCCTGAGTTTGGTCCGCGCCATCCCGCT
GCCAGGTCAGTGTGATCTCCGCAGGGTAGAAGCCCAGGGCCCAGCACCTCAGGGTGGCCT
CATGGTCAGAGATGGGGTGGTGGGTCACGTGTGTCTTTGGGGGGTCCGCGCGCTCCAGCG
TGTCCTTCCCGTTCTCCAGGTATCTGCGGAGCCACTCCACGCACGTGCCCTCCAGGTAGGC
TCTGTCCTGCTCCGCCACACGGGCCGCCTCCCACTTGCGCTGGGTGATCTGAGCCGCGGT
GTCCGCCGCGGTCCAGGAGCGCAGGTCCTCGTTCAGGGCGATGTAATCCTTGCCGTCGTA
GGCGTACTGGTTATGCCCGCGGAGGAGGCGCCCGTCCGGCCCCACGTCGCAGCCGTACAT
GCTCTGGAGGGTGTGAGACCCGGCCTCGCTCTGGTTGTAGTAGCCGCGCAGGTTCCGCAG
GCTCTCTCGGTCAGTCTGTGTGTTGGTCTTGAAGATCTGTGTGTTCCGGTCCCAATACTCCG
GCCCCTCCTGCTCTATCCACGGCGCCCGCGGCTCCTCTCTCGGACTCGCGGCGTCGCTGT
CGAACCTCACGAACTGCGTGTCGTCCACGTAGCCCACTGAGATGAAGCGGGGCTCCCCGC
GGCCGGGCCGGGACATGGCGGTGTCGAAATACCTCATGGAGTGGGATCCCATATGNNNNT
CNNCCNNNN
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>B82271-B44-2
gacgCGGCGgAcaCCGCGGCTCAGATCACCCAGCGCAAGTGGGAGGCGGCCCGTGTGGCGG
AGCAGGACAGAGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGGAGA
ACGGGAAGGACACGCTGGAGCGCGCGGACCCCCCAAAGACACACGTGACCCACCACCCCA
TCTCTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCGGAGATCAC
ACTGACCTGGCAGCGGGATGGCGAGGACCAAACTCAGGCCACTGAGCTTGTGGAGACCAG
ACCAGCAGGAGATAGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAG
CAGAGATACACATGCCATGTACAGCATGAGGGGCTGCCGAAGCCCCTCACCCTGAGATGGG
AGGGAGGTTCCGGCGGTCTGGTTCCGCGTGGCTCGTTAACTGATACACTCCAAGCGGAGAC
AGATCAACTTGAAGACGAGAAGTCTGCGTTGCAGACCGAGATTGCCAATCTACTGAAAGAGA
AGGAAAAACTGGAGTTCATCCTGGCCGCCCATTAAAAGCTTGAATTCCGATCCGGCTGCTAA
CAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCC
CTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATA
ATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAA
TGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTA
TTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAAT
AATATTTTGTTAAAATTCGCGTTAAATTTTTTGTTAAATCAGCTCATTTTTTTAACCAATAGGCC
GAAATCGGCAAAATCCCTTTATAAATCAAAAAGAATAGACCGANATAGGGGTTNNNNNGNTN
NNTNCCNNNNGNNNCANNNNCCACTATTNAAAGNAANNNNNNNNCNTNCCAANNNNCNAAN
NGGGGNNAAAAAAANCNNNNNNN
>B82271-B44-1
ggAGCGcAgGTCCTCGTTCAGGGCGATGTAATCCTTGCCGTCGTAGGCGTACTGgTTATGCC
CGCGGAGGAGGCGCCCGTCCGGCCCCACGTCGCAGCCGTACATGCTCTGGAGGGTGTGA
GACCCGGCCTCGCTCTGGTTGTAGTAGCCGCGCAGGTTCCGCAGGCTCTCTCGGTCAGTCT
GTGTGTTGGTCTTGAAGATCTGTGTGTTCCGGTCCCAATACTCCGGCCCCTCCTGCTCTATC
CACGGCGCCCGCGGCTCCTCTCTCGGACTCGCGGCGTCGCTGTCGAACCTCACGAACTGC
GTGTCGTCCACGTAGCCCACTGAGATGAAGCGGGGCTCCCCGCGGCCGGGCCGGGACAT
GGCGGTGTCGAAATACCTCATGGAGTGGGATCCCATATGTATATCTCCTTCTTAAAGTTAAA
CAAAATTATTTCTAGAGGGAAACCGTTGTGGTCTCCCTATAGTGAGTCGTATTAATTTCGCGG
GATCGAGATCCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCT
CCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGG
CGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCGCAGCCATGACCCAGTCACGTAGCGATAG
CGGAGTGTATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATTG
CGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTT
CCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTC
AAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCA
AAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGC
TCCGCCCCCCTGACGANCATCACAAAAATCGACGCTCAANNCAGAGGTGNNNAAACCCGAC
NGGGNNNANNAGATACCAGGNGTTTCCCCCNNNNNNCTCCCTCNNNGCGNNNNNNNCNNN
NCNNAACCCNNNNN
>B82271-T7
TctagaataATTTTGTTTAACTTTAAGAAGGAGATATACATATGGGATCCCACTCCATGAGGTATT
TCGACACCGCCATGTCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATCTCAGTGGGCTACG
TGGACGACACGCAGTTCGTGAGGTTCGACAGCGACGCCGCGAGTCCGAGAGAGGAGCCGC
GGGCGCCGTGGATAGAGCAGGAGGGGCCGGAGTATTGGGACCGGAACACACAGATCTTCA
AGACCAACACACAGACTGACCGAGAGAGCCTGCGGAACCTGCGCGGCTACTACAACCAGA
GCGAGGCCGGGTCTCACACCCTCCAGAGCATGTACGGCTGCGACGTGGGGCCGGACGGG
CGCCTCCTCCGCGGGCATAACCAGTACGCCTACGACGGCAAGGATTACATCGCCCTGAACG
AGGACCTGCGCTCCTGGACCGCGGCGGACACCGCGGCTCAGATCACCCAGCGCAAGTGG
GAGGCGGCCCGTGTGGCGGAGCAGGACAGAGCCTACCTGGAGGGCACGTGCGTGGAGTG
GCTCCGCAGATACCTGGAGAACGGGAAGGACACGCTGGAGCGCGCGGACCCCCCAAAGAC
ACACGTGACCCACCACCCCATCTCTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGGG
CTTCTACCCTGCGGAGATCACACTGACCTGGCAGCGGGATGGCGAGGACCAAACTCAGGC
CACTGAGCTTGTGGAGACCAGACCAGCAGGAGATAGAACCTTCCAGAAGTGGGCAGCTGTG
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GTGGTGCCTTCTGGAGAAGAGCAGAGATACACATGCCATGTACAGCATGAGGGGCTGCCGA
AGCCCCTCACCCTGAGATGGGAGGGAGGTTCCGGCGGTCTGGTTCCGCGTGGCTCGTTAA
CTGATACACTCCAAGCGGAGACAGATCAACTTGAAGACGAGAAGTCTGCGTTGCAGACCGA
GATTGCCAATCTACTGAAAGAGAAGGAAAAACTGGNNTTCATCCTGNNNGCCCATTAAAAGC
TTGAANTTCCGATCCNGGCNNCTAACAAANNCCNAAAAGGNANNNNNNNTTNGGGCNNCNN
CCCANCCNNNNNANNNAATNACNNNNNNNTNNNNNCCNNGNGGNNNNNNNNNNNAANNNN
NN
>B82271-T7-Term
cttcTTTCGGGCTTTGTTAGCAGCCGGATCGGAATTCAAGCTTTTAATGGGCGGCCAGGATGA
ACTCCAGTTTTTCCTTCTCTTTCAGTAGATTGGCAATCTCGGTCTGCAACGCAGACTTCTCGT
CTTCAAGTTGATCTGTCTCCGCTTGGAGTGTATCAGTTAACGAGCCACGCGGAACCAGACC
GCCGGAACCTCCCTCCCATCTCAGGGTGAGGGGCTTCGGCAGCCCCTCATGCTGTACATG
GCATGTGTATCTCTGCTCTTCTCCAGAAGGCACCACCACAGCTGCCCACTTCTGGAAGGTTC
TATCTCCTGCTGGTCTGGTCTCCACAAGCTCAGTGGCCTGAGTTTGGTCCTCGCCATCCCG
CTGCCAGGTCAGTGTGATCTCCGCAGGGTAGAAGCCCAGGGCCCAGCACCTCAGGGTGGC
CTCATGGTCAGAGATGGGGTGGTGGGTCACGTGTGTCTTTGGGGGGTCCGCGCGCTCCAG
CGTGTCCTTCCCGTTCTCCAGGTATCTGCGGAGCCACTCCACGCACGTGCCCTCCAGGTAG
GCTCTGTCCTGCTCCGCCACACGGGCCGCCTCCCACTTGCGCTGGGTGATCTGAGCCGCG
GTGTCCGCCGCGGTCCAGGAGCGCAGGTCCTCGTTCAGGGCGATGTAATCCTTGCCGTCG
TAGGCGTACTGGTTATGCCCGCGGAGGAGGCGCCCGTCCGGCCCCACGTCGCAGCCGTAC
ATGCTCTGGAGGGTGTGAGACCCGGCCTCGCTCTGGTTGTAGTAGCCGCGCAGGTTCCGC
AGGCTCTCTCGGTCAGTCTGTGTGTTGGTCTTGAAGATCTGTGTGTTCCGGTCCCAATACTC
CGGCCCCTCCTGCTCTATCCACGGCGCCCGCGGCTCCTCTCTCGGACTCGCGGCGTCGCT
GTCGAACCTCACGAACTGCGTGTCGTCCACGTAGCCCACTGAGATGAAGCGGGGCTCCCC
GCGGCCGGGCCGGGACATGGCGGNGTCGAAATACCTCATGGNNNNNNTCCCATATGNNTA
TCTCCTTNTNANNNNAAACAAAANTNATTTCNANNNGGNNAACCNNNNNNNNNNNNNCCCTN
NNNNNNGNANNNCNNNNNNTNNAANTTTNN
>B82291-B44-1
gAGcgcagGTCCTCGTTCAGGGCGATGTAATCCTTGCCGTCGTAGGCGTACTGGTTATGCCCG
CGGAGGAGGCGCCCGTCCGGCCCCACGTCGCAGCCGTACATGCTCTGGAGGGTGTGAGA
CCCGGCCTCGCTCTGGTTGTAGTAGCCGCGCAGGTTCCGCAGGCTCTCTCGGTCAGTCTGT
GTGTTGGTCTTGAAGATCTGTGTGTTCCGGTCCCAATACTCCGGCCCCTCCTGCTCTATCCA
CGGCGCCCGCGGCTCCTCTCTCGGACTCGCGGCGTCGCTGTCGAACCTCACGAACTGCGT
GTCGTCCACGTAGCCCACTGAGATGAAGCGGGGCTCCCCGCGGCCGGGCCGGGACATGG
CGGTGTCGAAATACCTCATGGAGTGGGATCCCATATGTATATCTCCTTCTTAAAGTTAAACAA
AATTATTTCTAGAGGGAAACCGTTGTGGTCTCCCTATAGTGAGTCGTATTAATTTCGCGGGAT
CGAGATCCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCC
GGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGTGAGCAGACAAGCCCGTCAGGGCGC
GTCAGCGGGTGTTGGCGGGTGTCGGGGCGCAGCCATGACCCAGTCACGTAGCGATAGCGG
AGTGTATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATTGCGG
TGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCCTC
GCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAG
GCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAG
GCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTTNCATAGGCTCC
GCCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGNCAGANGGTGGCGAAACCCGAC
NGGNNTATAAAGAATACCAGGGNNNNNNCCCCCCNN
>B82291-B44-2
gaCGcggcGgAcaCCGCGGCTCAGATCACCCAGCGCAAGTGGGAGGCGGCCCGTGTGGCGGa
gCAgGACAGAGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGGAGAA
CGGGAAGGACACGCTGGAGCGCGCGGACCCCCCAAAGACACACGTGACCCACCACCCCAT
CTCTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCGGAGATCACA
CTGACCTGGCAGCGGGATGGCGAGGACCAAACTCAGGACACTGCGCTTGTGGAGACCAGA
CCAGCAGGAGATAGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAG
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CAGAGATACACATGCCATGTACAGCATGAGGGGCTGCCGAAGCCCCTCACCCTGAGATGGG
AGGGAGGTTCCGGCGGTCTGGTTCCGCGTGGCTCGTTAACTGATACACTCCAAGCGGAGAC
AGATCAACTTGAAGACGAGAAGTCTGCGTTGCAGACCGAGATTGCCAATCTACTGAAAGAGA
AGGAAAAACTGGAGTTCATCCTGGCCGCCCATTAAAAGCTTGAATTCCGATCCGGCTGCTAA
CAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCC
CTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATA
ATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAA
TGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTA
TTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAAT
AATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCG
AAATCGGCAAAANCCCTTATAAATCAAAAGAATAGACCGNNATAGGGTTGANTGNNGTTNCN
NNTTNGNNNCNNGANTCCCNCTANTNAAGANNNNNNTCNNCNNNCAAGNNNNAAAAANCNN
CNNTCNNGNNNNNNNNNNCNNNCNNNNNNNNNNNN
>B82291-T7
tctagaatAATTTTgTTTAACTTTAAGAAGGAGATATACATATGGGATCCCACTCCATGAGGTATTT
CGACACCGCCATGTCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATCTCAGTGGGCTACGT
GGACGACACGCAGTTCGTGAGGTTCGACAGCGACGCCGCGAGTCCGAGAGAGGAGCCGC
GGGCGCCGTGGATAGAGCAGGAGGGGCCGGAGTATTGGGACCGGAACACACAGATCTTCA
AGACCAACACACAGACTGACCGAGAGAGCCTGCGGAACCTGCGCGGCTACTACAACCAGA
GCGAGGCCGGGTCTCACACCCTCCAGAGCATGTACGGCTGCGACGTGGGGCCGGACGGG
CGCCTCCTCCGCGGGCATAACCAGTACGCCTACGACGGCAAGGATTACATCGCCCTGAACG
AGGACCTGCGCTCCTGGACCGCGGCGGACACCGCGGCTCAGATCACCCAGCGCAAGTGG
GAGGCGGCCCGTGTGGCGGAGCAGGACAGAGCCTACCTGGAGGGCACGTGCGTGGAGTG
GCTCCGCAGATACCTGGAGAACGGGAAGGACACGCTGGAGCGCGCGGACCCCCCAAAGAC
ACACGTGACCCACCACCCCATCTCTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGGG
CTTCTACCCTGCGGAGATCACACTGACCTGGCAGCGGGATGGCGAGGACCAAACTCAGGA
CACTGCGCTTGTGGAGACCAGACCAGCAGGAGATAGAACCTTCCAGAAGTGGGCAGCTGTG
GTGGTGCCTTCTGGAGAAGAGCAGAGATACACATGCCATGTACAGCATGAGGGGCTGCCGA
AGCCCCTCACCCTGAGATGGGAGGGAGGTTCCGGCGGTCTGGTTCCGCGTGGCTCGTTAA
CTGATACACTCCAAGCGGAGACAGATCAACTTGAAGACGAGAAGTCTGCGTTGCAGANCGA
GATTGCCNATCTACTGAAAGAGAAGGAAAAAACTGGANTTCATCCNGNNNGCCCATTAAAAG
CTTGAANTNCCGATCCGGCNGCTAACAAANCCCNAAAGGNNGCNNANNNGGGNNNCNNCC
NNCNNNNNNANCCAATNACNANNNANNNNCCCNNNNGNGGGNNNNTNN
>B82291-T7-Term
ttTcggGCTTTGTTAGCAGCCGGATCGGAATTCAAGCTTTTAATGGGCGGccAGGATGAACtCca
GTTTTTCCTTCTCTTTCAGTAGATTGGCAATCTCGGTCTGCAACGCAGACTTCTCGTCTTCAA
GTTGATCTGTCTCCGCTTGGAGTGTATCAGTTAACGAGCCACGCGGAACCAGACCGCCGGA
ACCTCCCTCCCATCTCAGGGTGAGGGGCTTCGGCAGCCCCTCATGCTGTACATGGCATGTG
TATCTCTGCTCTTCTCCAGAAGGCACCACCACAGCTGCCCACTTCTGGAAGGTTCTATCTCC
TGCTGGTCTGGTCTCCACAAGCGCAGTGTCCTGAGTTTGGTCCTCGCCATCCCGCTGCCAG
GTCAGTGTGATCTCCGCAGGGTAGAAGCCCAGGGCCCAGCACCTCAGGGTGGCCTCATGG
TCAGAGATGGGGTGGTGGGTCACGTGTGTCTTTGGGGGGTCCGCGCGCTCCAGCGTGTCC
TTCCCGTTCTCCAGGTATCTGCGGAGCCACTCCACGCACGTGCCCTCCAGGTAGGCTCTGT
CCTGCTCCGCCACACGGGCCGCCTCCCACTTGCGCTGGGTGATCTGAGCCGCGGTGTCCG
CCGCGGTCCAGGAGCGCAGGTCCTCGTTCAGGGCGATGTAATCCTTGCCGTCGTAGGCGT
ACTGGTTATGCCCGCGGAGGAGGCGCCCGTCCGGCCCCACGTCGCAGCCGTACATGCTCT
GGAGGGTGTGAGACCCGGCCTCGCTCTGGTTGTAGTAGCCGCGCAGGTTCCGCAGGCTCT
CTCGGTCAGTCTGTGTGTTGGTCTTGAAGATCTGTGTGTTCCGGTCCCAATACTCCGGCCCC
TCCTGCTCTATCCACGGCGCCCGCGGCTCCTCTCTCGGACTCGCGNNGTCGCTGTCGAACC
TCACGAACTGCGTGTCGTCCACGTAGCCCACTGAGATGAAGCGGGGCTCCCCGCGGCCGG
GNCGGGACATGGNNGGNGNCGAAATACCTCATGGNNNGGGATCCCATATGNATATCTTNCT
TTCTTAAAGNTNAAAACAAAAATTTATTTTCNANNNNNNAANCCNNNNNNNGNNNNNCCCCN
NNNTANNGNNNNNNNNNNTNNATTTTTNNNNNNNNNGGGNNAANNNNNA
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>b2mm1-T7
tctagAataaTTTTgtTGAATTCGAGCTCGGTACCCGGGGATCCTAAGGAGGATATTAAAATGATC
CAGCGTACTCCAAAGATTCAGGTTTACTCACGTCATCCAGCAGAGAATGGAAAGTCAAATTT
CCTGAATTGCTATGTGTCTGGGTTTCATCCATCCGACATTGAAGTTGACTTACTGAAGAATGG
AGAGAGAATTGAAAAAGTGGAGCATTCAGACTTGTCTTTCAGCGCGGACTTGTCTTTCAGCG
CGGACTGGTCTTTCTATCTCTTGTACTACACTGAATTCACCCCCACTGAAAAAGATGAGTATG
CCTGCCGTGTGAACCATGTGACTTTGTCACAGCCCAAGATAGTTAAGTGGGATCGAGACATG
TAAAAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGA
ACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGNGGTCCCACCT
GACCCCATGCCGAACTCAGAAGTGAAACGCCGTANCGCCGATGGTAGTGTGGGGTCTCCC
CATGCGAGTGTNGGGAACCGNCNNNNNTCNTATAAAANGAAAGGCTCNGTCGAAAGANTGG
NCCTTTCGATTTNTNTNTTGTTTTTCTNTTTNTNNNNTTTGNNTNNNN
>b2mm1-pPLM4
CTcgatcCacTTaacTATCTTGGGCTGTGACAAAGTCACATGGTTCACACGGCAGGCATACTCaT
CTTTTTCAGTGGGGGTGAATTCAGTGTAGTACAAGAGATAGAAAGACCAGTCCGCGCTGAAA
GACAAGTCCGCGCTGAAAGACAAGTCTGAATGCTCCACTTTTTCAATTCTCTCTCCATTCTTC
AGTAAGTCAACTTCAATGTCGGATGGATGAAACCCAGACACATAGCAATTCAGGAAATTTGA
CTTTCCATTCTCTGCTGGATGACGTGAGTAAACCTGAATCTTTGGAGTACGCTGGATCATTTT
AATATCCTCCTTAGGATCCCCGGGTACCGAGCTCGAATTCAACAAAATTATTTCTAGAGGGA
AACCGTTGTGGTCTCCCTATAGTGAGTCGTATTAATTTCGCAGCTGGCGTAATAGCGAAGAG
GCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCT
GTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTG
CCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTtCCTTTCTCGCCACGTTCGCCGGC
TTTCCCCGTCAAGCT

